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Abstract
Targeted internal radionuclide therapy (TRT) would be
an effective alternative to current therapies for dissemi-
nated melanoma treatment. At our institution, a class of
iodobenzamides has been developed as potent melanoma-
seeking agents. This review described the preclinical vali-
dations of a quinoxaline derivative molecule (ICF01012)
as tracer for TRT application. It was selected for its high,
specific and long-lasting uptake in tumour with rapid clear-
ance from non-target organs providing suitable dosimetry
parameters for TRT. Extended in vivo study of metabolic
profiles confirmed durable tumoural concentration of the
unchanged molecule form. Moreover melanin specificity
of ICF01012 was determined by binding assay with syn-
thetic melanin and in vivo by SIMS imaging. Then, we
showed in vivo that [131I] ICF01012 treatment drastically
inhibited growth of B16F0, B16Bl6 and M4Beu tumours
whereas [131I] NaI or unlabelled ICF01012 treatment was
without significant effect. Histological analysis showed that
residual tumour cells exhibit a significant loss of aggres-
siveness after treatment. This anti-tumoural effect was
associated with a lengthening of the treated-mice survival
time and an inhibition of lung dissemination for B16Bl6
model.
Results presented here support the concept of TRT using
a [131I] labelled iodoquinoxaline derivative for an effective
melanoma treatment.
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Introduction
Melanoma is a poor prognosis skin cancer that affects about
150000 new patients per year in world. Despite recent advances
in prevention and early diagnosis, malignant melanoma remains
an increasingly prevalent cancer worldwide (Lorigan et al., 2008;
Thompson et al., 2005). It is notably the second most common
cancer among patients aged 20-39 years (Garbe and Leiter,
2009; Jennings and Murphy, 2009; Thompson et al., 2005).
This aggressive disease displays a strong tendency to
metastasize. Although localized disease is frequently curable
by surgical removal, there is no effective treatment for
metastatic melanoma. Patients with metastatic malignant
melanoma have an average median survival rate of 6 months
and a 5-year survival rate of less than 15% (Balch et al., 2001;
Miller and Mihm, 2006). There are several approved therapies
for malignant melanoma treatment as dacarbazine (an alkylating
agent) and interleukin-2. However, the response rate obtained
with these therapies remains low (less than 20%) and
contributes little to overall patient survival (Tarhini and
Agarwala, 2006). A higher response rate of up to 40% may be
obtained with combined treatment schedules, but without
significant prolonged survival in randomized studies
(Hauschild et al., 2001; Tarhini and Agarwala, 2006). Globally,
the response rate is still rather low and there has been no
progress in systemic palliative melanoma treatment for three
decades partly due to their high toxicity (Eigentler et al., 2003;
Garbe and Eigentler, 2007). In this context, there is an urgency
to develop more effective therapy and to find new more specific
ways to treat disseminated melanoma.
Identification of signalling pathways that are central to
melanoma initiation and progression, provides opportunity to
develop targeted therapies. Several clinical investigations are
under way in patients with melanoma testing these novel
agents (Bcl-2 antisense, BRAF inhibitors as BAY 43-9006, heat
shock protein 90 inhibitor, angiogenesis inhibitor, melanoma
vaccine strategies…) (Carlson et al., 2007; Gray-Schopfer et
al., 2007). At this time, it seems difficult to transpose the
encouraging results obtained in preclinical studies and no real
benefit in term of global survival has been demonstrated with
these agents (Bedikian et al., 2006; Fecher et al., 2008; Gray-
Schopfer et al., 2007). Involvement of these different targeted
pathways in the melanoma development as well as their
interactions must be better understood to exploit these new
strategies.
Targeted radionuclide therapy (TRT) is a potentially
important alternative to conventional therapeutic agents. In
comparison  with standard therapies (external beam
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radiotherapy or monochemotherapy), TRT offers the potential
of tumour-selective radio-therapeutic treatment of tumours and
distal metastases. This approach is under development for
several tumoural pathologies with success. First radio-
immunotherapy with name Zevalin® was approved by FDA in
2002 for treatment of non-Hodgkin’s lymphoma (Conti et al.,
2005; Wiseman et al., 2000).
Different carriers for radionuclides and melanoma targets
are being investigated. Peptide analogues of α-melanocyte
stimulating hormone (α-MSH) targeting melanocortin-1
receptor have been developed and provide good quality
imaging in melanoma-bearing mice (Miao et al., 2008; Miao
and Quinn, 2007; Ren et al., 2009). For a systemic radionuclide
therapy, promising experimental results in melanoma-bearing
mice have been reported (Miao et al., 2005; Miao and Quinn,
2008). However, high kidney concentration may results in a
restricting renal toxicity.
Melanin pigment itself can be a target for melanoma tissue.
Melanin is an amorphous, irregular polymer composed of
intimate mixtures of two separated but biogenetically related
pigments: eumelanins and pheomelanins (Prota, 2000).
Recently, radioimmunotherapy using mAb against melanin has
been developed and evaluated on nude mice bearing human
melanoma. Significant anti-tumoural effect has been obtained
but important renal uptake is also detected with this treatment
(Dadachova et al., 2004; Dadachova et al., 2008).
Many drugs bind to melanin both in vivo and in vitro:
polycyclic aromatic compounds such methylene blue (MTB),
chloroquine or acridine orange. An extended experimental work
has been done with 131I  or 211At labelled MTB giving some
promising data but without further clinical development (Link,
1999).
Another class of aromatic compounds with a cationic site
such as N-(2-diethylaminoethyl) iodobenzamide was
developed as potent melanoma-seeking agents. Two of these
compounds named respectively BZA and BZA2 have been
clinically evaluated as suitable imaging agents in nuclear
medicine with very encouraging results for metastases imaging
(Michelot et al., 1993; Moins et al., 2002). The BZA intracellular
localization within melanin-containing structures has been
clearly visualized with analytical imaging by secondary ion
mass spectrometry (Guerquin-Kern et al., 2005). Various
iodinated benzamides have been evaluated showing in vivo
distribution profiles with a high and specific tumour uptake
that was promising for imaging (Eisenhut et al., 2000; Moins et
al., 2001; Pham et al., 2007). However biodistribution profiles
of these tracers were not compatible for radiotherapy strategy
in term of potential delivered dose to the tumour.
Selection of ICF01012 tracer for targeted radionuclide
therapy of melanoma
Pharmacomodulation study: To discover new molecular
derivatives for targeted radionuclide therapy with strong,
Figure 1: (A) Chemical structure of BZA2 and ICF01012. (B) Representative scintigraphic planar images of a B16F0-bearing C57Bl6 mouse. Mice were
injected intravenously with 3.7 MBq [125I] ICF01012. Images were acquired at 1, 6, 24, 72 hours and 8 days after injection. Tumours were easily visualized
(T) suggesting a significant [125I] ICF01012 tumoural concentration. Moreover rapid systemic elimination was quite complete from non target organs 24
hours p.i. (Miot-Noirault et al., 2009) (C) Representative whole-body autoradiography of a mouse bearing B16F0 melanoma cell xenograft, 72 h after i.v.
injection of 1.7 MBq (0.1 µmol) [125I] ICF01012. T: Tumour; E: eyes. (D) Tumoural distribution radioactivity in nude mice bearing B16F0 melanoma cell
xenograft after i.v. injection of [125I] ICF01012 and [125I] BZA2.
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specific and long-lasting uptake in melanoma tissues, a large
pharmacomodulation study was performed (Chezal et al., 2008).
This strategy involved the incorporation of aromatic or
heteroaromatic structures in place of the phenyl moiety of BZA2
to take advantage of polycyclic aromatic compounds that
display a strong affinity for melanin, while the lipophilic side
chain was kept identical. Then, various iodo (hetero) aromatic
fused ring systems with a carboxamide part were synthesized
and radioiodinated. Biodistribution of these coumpounds
radiolabelled with 125I was performed in B16F0 melanoma
bearing C57BL6 mice after i.v. injection. The radioactivity
biodistribution was analysed by quantitative whole body
autoradiography using an AMBIS 4000 detector on whole body
slices of mice obtained by cryosection. The radioactivity was
quantified in different organs including tumour and expressed
as percentage of injected dose/g of tissue (%ID/g). Dosimetry
parameters for a 131I utilization were extrapolated using an
adaptation of the MIRD program. From this study a quinoxaline
derivat ive molecule (N-(2-diethylaminoethyl)-6-
iodoquinoxaline-2-carboxamide dihydrochloride salt named
ICF01012) was selected for its high, specific and long-lasting
uptake in B16F0 tumour  with a rapid clearance from non-target
organs (Figure 1) (Chezal et al., 2008). In comparison with [125I]
BZA2 (Chezal et al., 2008; Moins et al., 2001), we observed for
[125I] ICF01012 a more elevated and durable concentration on
B16F0 tumour (Figures 1A and 1B). At the stage 72 h p.i., the
tumour concentration was increased up to 11 fold as compared
to BZA2 (Figure 1D). In term of dosimetry, for a 131I labelling,
the tumour absorbed dose was increased by more than 5 fold.
Pharmacokinetic pofiles: [125I] CF01012 biodistribution in
B16F0-bearing C57Bl6 mice to 1 hour from 8 days post-injection
was analysed by quantitative whole body autoradiography
(AMBIS 4000) (Chezal  et al. ,  2008). Radioactivity
quantifications expressed as percentage of injected dose/g of
tissue (%ID/g) were reported for different organs including
tumour in Table 1. [125I] ICF01012 tumoural concentration was
significantly observed as early as 1 hour p.i and a significant
and durable accumulation until 8 days p.i demonstrating a very
high tumour uptake. Moreover the cumulative urinary and fecal
Journal of Cancer Science & Therapy  - Open Access
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excretions collected up to 72 h showed that elimination was
almost total (88%) with a mainly urinary route (70%) (Chezal et
al., 2008). SPECT imaging of B16F0-bearing C57Bl6 mice injected
intravenously with [125I] ICF01012 confirmed this pharmakinetic
profile (Figure 1B). Indeed tumours were easily visualized
suggesting a significant [125I] ICF01012 tumoural concentration
(Miot-Noirault et al., 2009). Moreover systemic elimination was
quite complete from non target organs 24 hours p.i confirming
the rapid clearance from non target tissues obtained with
autoradiography quantitation (Table 1). 24 hours post-injection,
radioactivity concentration was very low within liver (<1.5%
ID/g), and undetectable in spleen, kidneys, lungs, blood (Table
1). This led to high tumour to nontarget organ activity ratios
rapidly unquantifiable when organ concentration was within
the range of the background value (Table 1). Interestingly,
[125I] ICF01012 renal uptake is very low (undetectable 24 hours
after injection) by comparison with other targeting-melanin
molecules as antibodies and α-MSH peptide analogues
(Dadachova et al., 2008; Miao et al., 2005).
To trace and quantify the metabolic fate of [125I] ICF01012 in
B16F0 melanoma bearing mice, high-performance liquid
chromatography (HPLC) analysis were performed on tumour
(Denoyer et al., 2008). Many HPLC peaks were identified in
tumoural extracts with the major peak corresponding to the
non-metabolized form of [125I] ICF01012. Eight days post-
injection, 83.6% of the remaining radioactivity is under [125I]
ICF01012 unchanged form.
All these promising data made this tracer a strong melanoma
seeking agent for both scintigraphic imaging and radionuclide
therapy (Chezal et  al., 2008).
Melanin specificity: In experiments presented above, we
observed B16F0 melanoma targeting using our quinoxaline
analogue tracer. We verified the melanin specificity of [125I]
ICF01012 using a binding assay with synthetic melanin. We
showed that [125I] ICF01012 displayed a strong affinity for
synthetic melanin in water and in PBS (Chezal et al., 2008).
Additional study was performed to visualised in vivo ICF01012
melanin specificity by Secondary ion mass spectrometry
Table 1: Biodistribution of radioactivity (%ID/g)  in C57Bl6 mice bearing B16 melanoma at various time after i.v. injection of [125I] ICF01012. Melanoma/
Organ Ratios of [125I] ICF01012 at 6 and 24 hours p.i.
 
Hours p.i. 1 3 6 24 72 120 192 6 24
Tumour 21,99±7,25 27,38±6,27 37,24±7,12 20,67±6,38 12,45±1,61 5,37±3,18 3,77±0,43 1 1
Brain 2,17±0,83 0,52±0,73 0,39±0,47 0,06±0,08 UD UD UD 95,5 344,5
Stomach 22,06±5,35 20,6±4,98 21,35±3,02 0,96±1,12 2,23±0,38 UD UD 1,7 21,5
Liver 13,95±1,32 8,77±1,11 7,69±0,65 1,51±0,08 UD UD UD 4,8 13,7
Bone 
Marrow 4,7±0,45 ND 0,34±0.69 UD UD UD UD 109,5 ND
Muscle 2,06±0,06 0,88±0,17 0,84±0,07 0,00±0,05 UD UD UD 44,3 5167,5
Lung 7,96±0,74 5,7±0,31 3,91±0.71 0,18±0.26 UD UD UD 9,5 114,8
Spleen 15,6±14,99 2,35±3,32 1,39±1.62 0,11±0.14 UD UD UD 26,8 187,9
Kidney 16,03±0,54 8,95±2,44 7,23±0.64 0,49±0.57 UD UD UD 5,2 42,2
Blood 2,89±0,67 2,9±0,06 3,19±0.19 0,4±0.12 UD UD UD 11,7 51,7
Uvea 30,75±4,78 24,79±0,08 30,52±5.27 30,06±3.58 25,26±8.38 17,21±6.67 15,34±1.44 1,2 0,7
ND: Not Determined; UD: Undetected
Ratio Tumour vs organ 
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(SIMS) imaging (Bonnet-Duquennoy et al., 2009). With this
technique, we observed a perfect co-localization of ICF01012
signal with melanin confirming the melanin binding properties
of this tracer and its internalization in melanoma cells.
Moreover, we noted on biodistribution study (Table 1) an
important radioactivity concentration on uvea confirming the
high ICF01012 specificity for pigmented structures and so for
melanin (Chezal et al., 2008). However fixation of tracer on
normal pigmented tissues in these pre-clinical experiments
should not be considered as a limit for our strategy. Indeed
these experiments were performed on the heavily pigmented
C57BL/6J mice associated with an important uveal melanin
content which is not predictive for human status of uvea. On
a clinical imaging study with [123I] BZA2, the parental benzamide
analogue of ICF01012, no significant uveal uptake was imaged
excepted for an ocular melanoma case while important uveal
uptake was observed with the same tracer on this mouse model
(Moins et al., 2002; Sillaire-Houtmann et al., 2004). Because of
murine and human differences on ocular geometry and melanin
content, ICF01012 accumulation within C57Bl6 mice eyes should
not be considered as hampering for clinical transfer of this
radiotherapy concept. Nevertheless this point has to be taking
into account in our studies.
In vivo anti-tumoural efficacy of TRT
Several radionuclides are developed for the treatment of
oncological diseases. Various approaches using 131I for TRT
were developed to treat different cancers because of its
relatively low beta energy with a maximum range of 3 mm in
tissue which is effective for treatment (Kassis and Adelstein,
2005). Some of them have resulted in very good curative
responses like 131I treatment of thyroid cancer and its
micrometastases (Nijsen et al., 2007; Verburg et al., 2005).
Biodistribution properties of [125I] ICF01012 molecule provide
suitable dosimetry parameters using a labelling with 131I. Indeed
an administered dose of 37 MBq will allow the delivery of 49
Gy to the tumour, a usefully high dose for a good therapeutic
efficacy (Chezal et al., 2008).
We investigated the in vivo therapeutic efficacy of [131I]
ICF01012 as a radionuclide therapeutic agent (Bonnet-
Duquennoy et al., 2009) on murine melanoma models B16F0
and on the metastatic B16Bl6 cell lines grafted s.c. into syngenic
C57Bl/6J mice (Poste et al., 1980). [131I] ICF01012 was
administered i.v. at days 6 and 10 (2x18.5 MBq). Control groups
received [131I] Na or unlabelled ICF01012 (equimolar dose). All
groups contained at least 10 animals and experiments were
performed twice. The survival of [131I] ICF01012-treated mice,
with a median of 39 days, was significantly (p=0.006) better
than that of untreated group whereas that of [131I] NaI-treated
mice was similar (p=0.3). These results suggested that [131I]
ICF01012 treatments showed low toxicity confirming precedent
pharmacokinetic experiments and rapid systemic elimination.
We observed that the treatment with unlabelled ICF01012
was without any significant effect whereas [131I] ICF01012
treatment drastically suppressed the growth of both B16F0
(p=0.001) and B16Bl6 (p=0.009) tumours. Figure 2A illustrates
the strong difference on B16Bl6 tumour size at day 19 between
control and treated animals.  [131I] NaI alone did not have any
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efficacy against tumour growth showing interest of targeting
strategy with [131I] ICF01012 for an efficient therapeutic effect
(Bonnet-Duquennoy et al., 2009).
In term of proliferation, the tumour volume doubling time
(DT) was determined to quantify precisely the tumoural growth.
After [131I] ICF01012 treatment, DT was significantly increased
(range +44 to +147%) confirming inhibition of tumoural growth.
Histological analysis showed that after targeted radiotherapy
treatment, residual tumoural cells exhibited a decrease of mitotic
index and microvessel  numbers and an increase of
anisocytosis. This effect was associated with a significant
decrease of the tumoural PCNA proliferation marker expression
after  treatment. All these results suggested a loss of
aggressiveness of residual tumour cells after [131I] ICF01012
treatment (Bonnet-Duquennoy et al., 2009).
After macroscopic analysis, we observed that 55% of the
untreated mice bearing B16Bl6 tumours had lung metastases
whereas no metastasis was counted on [131I] ICF01012 treated
group (Figure 2B) suggesting an inhibitory effect of this
treatment on lung dissemination (Bonnet-Duquennoy et al.,
Figure 2: Illustrations of significant anti-tumoral effect of TRT using
[131I]ICF01012 treatment on B16Bl6 tumoural growth (A) and B16Bl6
dissemination on lung (B). [131I]ICF01012 treatment was administered
intravenously at days 6 and 10 (2x18.5MBq) in C57Bl6 mice bearing
B16Bl6 palpable tumours. (A) Observation of untreated and treated mice
bearing B16Bl6 by computed tomography. Animal imaging was performed
by using the GE eXplore CT 120 micro-CT scanner (GE Healthcare,
London, Canada). The micro-CT image acquisition consisted of 220 views
were acquired in 0.88° increments around the animal collected in one full
rotation of the gantry, with 32 ms exposure per view. The X-ray tube
settings were 70 kV and 50 mA. The resulting raw data were reconstructed
to a final image volume of 0.989 x 0.989 x 0.989 µm. The reconstructed
slices were output in the CT manufacturer’s raw format and were corrected
equal to Hounsfield units. (B) Macroscopic observation of representative
lung of untreated and treated mice. No metastasis was detected on treated
animals (0/25) whereas 55% of untreated mice exhibited dissemination
(12/22).
T
Untreated Treated
10 mm 10 mm0 mm
Untreated Treated
A
B
T
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2009). We demonstrated a strong and similar anti-tumoural
effect of [131I] ICF01012 on both nonmetastatic B16F0 tumour
and the more aggressive metastatic B16Bl6 model and a
complete inhibition of B16Bl6 dissemination towards lungs.
These results provide useful data for support our approach to
treating all melanoma forms including disseminated disease.
Because B16F0 and B16Bl6 tumours were highly pigmented,
we assessed radiotherapy experiment on human melanoma cells
which exhibit lower melanin content (Bonnet-Duquennoy et
al., 2009). Tumour distribution of radiotracer was evaluated on
nude mice bearing M4Beu melanoma which contain a lower
melanin concentration than B16F0 tumour (ratio: 1/2.8) (Bonnet-
Duquennoy et al., 2009). We observed that M4Beu tumour
uptake of [125I] ICF01012 was consistent with 6.3±1.3% and
2.3±0.5% ID/g 6 and 24 hours after injection respectively but
lower than B16F0 tumour uptake (Bonnet-Duquennoy et al.,
2009). Then targeted radiotherapy was evaluated using 2
injections of 18.5 MBq [131I] ICF01012 into nude mice bearing
M4Beu tumours. In term of proliferation, the tumor DT were
significantly increased (range +46%) after [131I] ICF01012
treatment. These results showed that treatment significantly
slowed the M4Beu tumoural growth (p=0.003) confirming
strong efficacy of this TRT strategy even in melanoma
containing lower target concentration.
Discussion
Our data demonstrated a strong anti-tumoural efficacy
associated with low toxicity of [131I] ICF01012 for radionuclide
therapy on murine and human pigmented melanoma models
whatever their dissemination profiles and their melanin content
be. In melanoma, melanin is observed within tumoural cells,
into extracellular space and in melanophages (Lazova et al.,
2009; Revskaya et al., 2009). In this project we proved that 131I
radionuclide physical proprieties associated with this melanin
target distribution  was able to deliver efficient cytotoxic
irradiation (Bonnet-Duquennoy et al., 2009; Chezal et al., 2008).
Considering that melanin is detected in more than 90% of
melanoma cases, strategy targeting this pigment could be used
in the majority of patients.
Optimization of the therapy protocol in mice with lower doses
and other schedules of injections will be explored in order to
define the better balance between the anti-tumoural effect and
the safety on normal pigmented tissues. Interestingly
histological evaluation of B16F0 and B16Bl6 tumours in treated
mice revealed an increased of extracellular melanin content
after radiotherapy providing more abundant target for new
injection. [131I] ICF01012 treatments used in this strategy
showed low toxicity with an increase of median survival time
confirming in vivo pharmacokinetic profile of ICF01012 which
demonstrated a rapid clearance of tracer from non-target organs
as liver, brain and lung. Additional dosimetric studies are in
progress to evaluate the delivery dose in the different organs
in these therapeutic conditions by taking into account
evolution of the tumoural size. This work should allow to better
manage the future protocol and to predict the anti-tumoural
response for clinical transfer of this strategy. Furthermore, an
imaging clinical trial will be performed to evaluate tumour and
possible normally pigmented organ fixation of ICF01012 and
to determine dosimetric parameters in human.
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Results presented here support the concept of targeted
radionuclide therapy using a [131I] labelled iodoquinoxaline
derivative for an effective melanoma treatment.
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